Abbott Laboratories (NYSE:ABT) is being projected to post an EPS of $0.59 for the quarter ended 2016-09-30. 7 days ago the estimate stood at $0.59 and 30 days ago at $0.59. Similarly, the projected figure 60 days ago was $0.59 and 90 days ago it was $0.59.
The estimates have seen a change of 0% from 7 days ago. During this period, the figure was upwards 0 times and downwards 0 times. During the last 180 days upwards revision in the EPS estimate happened 0 times and downwards revision happened 4 times.
The number of revisions upwards was 1 in 30 days, 7 in 60 days, 7 in 90 days and 7 in 120 days.
The number of revisions downwards was 0 in the last 30 days, 1 in the last 60 days, 1 in the last 90 days and 1 in the last 120 days.
For the quarter ended 1, Abbott Laboratories (NYSE:ABT) had a mean EPS estimate of $0.59 out of 12 estimates. When the actual figure was announced on 2016-04-20 it was $0.41, giving a surprise margin of $0.02 or 5.13% per share. The actual EPS yielded a standard deviation of 0.01 from all estimates.
Quarterly Sales Estimates
2 analysts gave Abbott Laboratories (NYSE:ABT) an annual sales estimate of $6112.1, if the arithmetic mean of the estimates is considered. The estimate stands at $6112.1 if the median is considered. The estimates are for the year 2018. The estimates range from a low of $6082.2 to a high of $6142, with the standard deviation of the estimates being 42.284%.
In the last week, 2 analysts increased their sales estimate while 2 decreased it. The change in the mean estimate for the period is 0%.
In the last month, 2 analysts increased their sales estimate while 2 decreased it. The change in the mean estimate for the period is 0.492%.
In last 3 months, 2 analysts increased their sales estimate while 2 decreased it. The change in the mean estimate for the period is 1.02%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...